Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3349518 | 0.86 | ALDH1A1 (0.49) | TSHRALDH1A1L3MBTL1NPC1RAB9A | |
| SCHEMBL5242540 | 0.81 | MME (0.47) | TSHRALDH1A1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL5242531 | 0.81 | MME (0.47) | TSHRALDH1A1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL4905957 | 0.79 | TSHR (0.44) | TSHRALDH1A1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL4905986 | 0.79 | TSHR (0.44) | TSHRALDH1A1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL4905938 | 0.77 | NPC1 (0.47) | TSHRALDH1A1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL4905921 | 0.77 | NPC1 (0.47) | TSHRALDH1A1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL4968655 | 0.77 | MEN1 (0.57) | TSHRALDH1A1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL3406444 | 0.75 | F10 (0.41) | TSHRALDH1A1L3MBTL1LMNA | |
| SCHEMBL3347335 | 0.75 | F10 (0.41) | TSHRALDH1A1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080311609-A1 | Novel Molecular Probes | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080311609-A1 | Novel Molecular Probes | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080311609-A1 | Novel Molecular Probes | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1831187-A1 | NOVEL MOLECULAR PROBES | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006065218-A1 | NOVEL MOLECULAR PROBES | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311609-A1 | Novel Molecular Probes | BACE1, BACE2, PSEN1 | TSHR 4617/4885ALDH1A1 1417/4885L3MBTL1 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.